[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615257":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":256,"collaborators":22,"id":258,"slug":259,"hasResults":260,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":22,"eligibilityCriteria":263,"healthyVolunteers":260,"sex":264,"minAge":265,"maxAge":22,"enrollmentInfo":266,"targetDuration":22,"studyType":269,"phases":270,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":293},{"fullName":5,"class":6},"Mirum Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Livmarli","EXPERIMENTAL","ALGS: Primary cohort with a minimum of 45 previously untreated (treatment naïve). Supplemental cohort of participants who have previously received Livmarli.\n\nPFIC: Patients with Progressive Familial Intrahepatic Cholestasis treated with Livmarli. The study will enroll a minimum of 130 patients with PFIC",[13],"Drug: Livmarli Oral Product",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Livmarli Oral Product","Participants will be treated according to standard of care for the duration of the study and Schedule of Assessments.",[9],[21],"Maralixibat",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Clinical Trials Mirum","CONTACT","+16506674085","clinicaltrials@mirumpharma.com",[30,48,62,79,94,109,124,138,152,167,183,197,213,227,243],{"facility":31,"status":32,"city":33,"state":22,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Cliniques Universitaires Saint Luc (UCLouvain)","RECRUITING","Brussels","1200","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.34878,50.85045,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":22,"email":47},"Stephenne Xavier","+32 2 764 13 77","xavier.stephenne@uclouvain.be",{"facility":49,"status":32,"city":50,"state":22,"zip":51,"country":35,"countryCode":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"University Hospital Gent (UZ Gent)","Ghent","9000",{"type":38,"coordinates":53},[54,55],3.71667,51.05,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":60,"phoneExt":22,"email":61},"Ruth De Bruyne","+32 9 332 39 66","ruth.debruyne@ugent.be",{"facility":63,"status":32,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Hospices Civils de Lyon - Hopital Femme Mère Enfant","Bron","Auvergne-Rhône-Alpes","69500","France","FR",{"type":38,"coordinates":70},[71,72],4.91303,45.73865,{"lat":72,"lon":71},[75],{"name":76,"role":26,"phone":77,"phoneExt":22,"email":78},"Mathias Ruiz","+33 472 35 70 50","mathias.ruiz@chu-lyon.fr",{"facility":80,"status":32,"city":81,"state":82,"zip":83,"country":67,"countryCode":68,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"CHU de Toulouse - Hôpital des Enfants","Toulouse","Occitanie","31049",{"type":38,"coordinates":85},[86,87],1.44367,43.60426,{"lat":87,"lon":86},[90],{"name":91,"role":26,"phone":92,"phoneExt":22,"email":93},"Nolwenn Laborde","+33.(0)5 34558566","laborde.n@chu-toulouse.fr",{"facility":95,"status":32,"city":96,"state":97,"zip":98,"country":67,"countryCode":68,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Bicetre University Hospital","Le Kremlin-Bicêtre","Île-de-France Region","94270",{"type":38,"coordinates":100},[101,102],2.36073,48.81471,{"lat":102,"lon":101},[105],{"name":106,"role":26,"phone":107,"phoneExt":22,"email":108},"Emmanuel Gonzales","+33 1 45 21 37 88","emmanuel.gonzales@aphp.fr",{"facility":110,"status":32,"city":111,"state":22,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Charite Berlin","Berlin","13353","Germany","DE",{"type":38,"coordinates":116},[117,118],13.41053,52.52437,{"lat":118,"lon":117},[121],{"name":122,"role":26,"phone":22,"phoneExt":22,"email":123},"Philip Bufler","philip.bufler@charite.de",{"facility":125,"status":32,"city":126,"state":22,"zip":127,"country":113,"countryCode":114,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Children's University Hospital Essen","Essen","45149",{"type":38,"coordinates":129},[130,131],7.01228,51.45657,{"lat":131,"lon":130},[134],{"name":135,"role":26,"phone":136,"phoneExt":22,"email":137},"Elke Lainka","+49 (0)201 723 3360","Elke.Lainka@uk-essen.de",{"facility":139,"status":32,"city":140,"state":22,"zip":141,"country":113,"countryCode":114,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"University Hospital Hamburg-Eppendorf","Hamburg","20246",{"type":38,"coordinates":143},[144,145],9.99302,53.55073,{"lat":145,"lon":144},[148],{"name":149,"role":26,"phone":150,"phoneExt":22,"email":151},"Sebastian Schulz-Jürgensen","+49 40 7410 52702","s.schulz-juergensen@uke.de",{"facility":153,"status":154,"city":155,"state":22,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"2nd Paediatric Clinic P &A Kyriakou Children's Hospital","NOT_YET_RECRUITING","Athens","11527","Greece","GR",{"type":38,"coordinates":160},[161,162],23.72784,37.98376,{"lat":162,"lon":161},[165],{"name":166,"role":26,"phone":22,"phoneExt":22,"email":22},"Aglaia Zellos",{"facility":168,"status":32,"city":169,"state":170,"zip":171,"country":172,"countryCode":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"AO Ospedale PAPA GIOVANNI XXIII","Bergamo","Lombardy","24126","Italy","IT",{"type":38,"coordinates":175},[176,177],9.66721,45.69601,{"lat":177,"lon":176},[180],{"name":181,"role":26,"phone":22,"phoneExt":22,"email":182},"Lorenzo D'Antiga","ldantiga@asst-pg23.it",{"facility":184,"status":32,"city":185,"state":186,"zip":187,"country":172,"countryCode":173,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Istituto mediterraneo trapianti - ISMETT","Palermo","Sicily","90127",{"type":38,"coordinates":189},[190,191],13.3636,38.1166,{"lat":191,"lon":190},[194],{"name":195,"role":26,"phone":22,"phoneExt":22,"email":196},"Giusy Ranucci","granucci@ismett.edu",{"facility":198,"status":32,"city":199,"state":22,"zip":200,"country":201,"countryCode":202,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"University Medical Center Groningen (UMCG)","Groningen","9713GZ","Netherlands","NL",{"type":38,"coordinates":204},[205,206],6.56667,53.21917,{"lat":206,"lon":205},[209],{"name":210,"role":26,"phone":211,"phoneExt":22,"email":212},"Henkjan Verkade","+31 50 3614147","h.j.verkade@umcg.nl",{"facility":214,"status":154,"city":215,"state":22,"zip":216,"country":217,"countryCode":218,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Unidade Local de Saude de Coimbra Paediatric Department Avenida Afonso Romăo","Coimbra","3000-602","Portugal","PT",{"type":38,"coordinates":220},[221,222],-8.41996,40.20686,{"lat":222,"lon":221},[225],{"name":226,"role":26,"phone":22,"phoneExt":22,"email":22},"Isabel Goncalves Costa",{"facility":228,"status":32,"city":229,"state":230,"zip":231,"country":232,"countryCode":233,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"Hospital Universitairo Vall D'Hebron","Barcelona","Catalonia","08035","Spain","ES",{"type":38,"coordinates":235},[236,237],2.15899,41.38879,{"lat":237,"lon":236},[240],{"name":241,"role":26,"phone":22,"phoneExt":22,"email":242},"Jesus Quintero","jesus.quintero@vallhebron.cat",{"facility":244,"status":32,"city":245,"state":22,"zip":246,"country":232,"countryCode":233,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"Hospital Universitario La Paz","Madrid","28046",{"type":38,"coordinates":248},[249,250],-3.70256,40.4165,{"lat":250,"lon":249},[253],{"name":254,"role":26,"phone":22,"phoneExt":22,"email":255},"Esteban Frauca Remacha","esteban.frauca@salud.madrid.org",{"type":257,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100615257","phase-4-long-term-low-intervention-safety-and-clinical-outcomes-clinical-study-of-livmarli-in-patients-with-alagille-syndrome-or-progressive-familial-intrahepatic-cholestasis-in-the-european-union-leap-eu-100615257",false,"NCT07290257","Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)","Inclusion Criteria:\n\n* Understand and execute an Informed consent and assent (as applicable)\n* For participants with ALGS ≥2 months of age at Day 1\n* For participants with PFIC, ≥3 months of age at Day 1\n* A clinically and\u002For genetically confirmed ALGS diagnosis with pruritus secondary to chronic cholestasis, or a clinically and\u002For genetically confirmed PFIC diagnosis\n* For the ALGS primary cohort: Initiation of Livmarli at the time of study entry\n* For the ALGS supplemental cohort, : Actively using Livmarli prior to study entry\n* For participants with PFIC: Prescribed Livmarli at the time of study entry or prior to study entry\n\nExclusion Criteria:\n\n* History of Liver Transplant\n* Any Livmarli contraindications (as per SmPC)\n* Any condition or abnormality that, in the opinion of the investigator, may interfere with the participation in or completion of the study\n* Received an investigational drug within 30 days before the first dose of Livmarli (Participation in previous maralixibat studies or expanded-access programs is acceptable.)\n* Received another IBAT inhibitor within 7 days before the first dose of Livmarli\n* Baseline data before start of treatment of Livmarli are unavailable (\\\u003C2 values before treatment) for key safety (LFTs, FSV laboratory results) and key efficacy (sBA, pruritus) parameter","ALL","2 Months",{"count":267,"type":268},230,"ESTIMATED","INTERVENTIONAL",[271],"PHASE4","In patients with Alagille syndrome (ALGS), the key objectives are to evaluate the tolerability, long-term safety (including possible liver toxicity) and long-term efficacy of Livmarli treatment.\n\nIn patients with Progressive Familial Intrahepatic Cholestasis (PFIC), the key objectives are to evaluate tolerability, long-term safety (including possible liver toxicity and potential impact of chronic exposure to propylene glycol (PG)), long-term efficacy, and growth and development.",[274,275],"Alagille Syndrome","Progressive Familial Intrahepatic Cholestasis",[277,278,274,9,21,279,280,281,282,283],"ALGS","Liver Diseases","Cholestasis","Pruritus","Itching","IBAT inhibitor","PFIC","2026-06-18",{"date":286,"type":287},"2026-06-23","ACTUAL",{"date":289,"type":287},"2025-09-25",{"date":291,"type":268},"2030-12-22",{"name":5,"class":6},15]